Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes
- 12 January 2015
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 21 (2) , 173-177
Abstract
Type 2 diabetes is a major health problem worldwide, and one of its key features is the inability of elevated glucose to stimulate the release of sufficient amounts of insulin from pancreatic beta cells to maintain normal blood glucose levels. New therapeutic strategies to improve beta cell function are therefore believed to be beneficial. Here we demonstrate that the short-chain fatty acid receptors FFA2 (encoded by FFAR2) and FFA3 (encoded by FFAR3) are expressed in mouse and human pancreatic beta cells and mediate an inhibition of insulin secretion by coupling to Gi-type G proteins. We also provide evidence that mice with dietary-induced obesity and type 2 diabetes, as compared to non-obese control mice, have increased local formation by pancreatic islets of acetate, an endogenous agonist of FFA2 and FFA3, as well as increased systemic levels. This elevation may contribute to the insufficient capacity of beta cells to respond to hyperglycemia in obese states. Indeed, we found that genetic deletion of both receptors, either on the whole-body level or specifically in pancreatic beta cells, leads to greater insulin secretion and a profound improvement of glucose tolerance when mice are on a high-fat diet compared to controls. On the other hand, deletion of Ffar2 and Ffar3 in intestinal cells did not alter glucose tolerance in diabetic animals, suggesting these receptors act in a cell-autonomous manner in beta cells to regulate insulin secretion. In summary, under diabetic conditions elevated acetate acts on FFA2 and FFA3 to inhibit proper glucose-stimulated insulin secretion, and we expect antagonists of FFA2 and FFA3 to improve insulin secretion in type 2 diabetes.Keywords
This publication has 46 references indexed in Scilit:
- The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43Nature Communications, 2013
- Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent MechanismsPLOS ONE, 2012
- A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretionJournal of Clinical Investigation, 2011
- Type 2 diabetes across generations: from pathophysiology to prevention and managementThe Lancet, 2011
- Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implicationsTrends in Endocrinology & Metabolism, 2010
- The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in miceJournal of Clinical Investigation, 2010
- Lipid receptors and islet function: therapeutic implications?Diabetes, Obesity and Metabolism, 2009
- Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41Proceedings of the National Academy of Sciences, 2008
- Probing cell type–specific functions of Gi in vivo identifies GPCR regulators of insulin secretionJournal of Clinical Investigation, 2007
- Dual Roles for Glucokinase in Glucose Homeostasis as Determined by Liver and Pancreatic β Cell-specific Gene Knock-outs Using Cre RecombinaseJournal of Biological Chemistry, 1999